The alpha-1 antitrypsin deficiency market is projected to grow from USD 3.8 billion in 2025 to USD 12.7 billion by 2035, at a CAGR of 12.8%. Augmentation Therapy will dominate with a 46.3% market share, while hospitals will lead the application segment with a 41.8% share.